Completed PHASE3 INTERVENTIONAL NCT00217230

Trial To Assess Safety And Efficacy Of Influenza Virus Vaccine, Trivalent, Types A & B, Live Cold-Adapted (CAIV-T) In Adults Aged 60 Years And Older

A Prospective, Randomized, Double-Blind, Placebo-Controlled Trial To Assess Safety And Efficacy Of Influenza Virus Vaccine, Trivalent, Types A & B, Live Cold-Adapted (CAIV-T) In Adults Aged 60 Years And Older CAIV-T, Liquid Formulation

Sponsor: MedImmune LLC

Conditions Influenza

Interventions CAIV-T

Updated 5 times since 2017 Last updated: Oct 2, 2006 Started: Apr 30, 2001 Completion: Nov 30, 2001

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Influenza and is currently completed. MedImmune LLC leads this study, which shows 5 recorded versions since 2001 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Apr 2001

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

MedImmune LLC
Wyeth is now a wholly owned subsidiary of Pfizer

Data source: MedImmune LLC

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Tygerberg, South Africa